Business
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update. "In recent months, we have continued
About this update from Jasper Therapeutics, Inc.
[{"type":"image","alt":"Jasper Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Jasper Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":107,"url":"https://media.zenfs.com/en/globenewswire.com/3e2f430d18dcba99f4639e0554ffa243"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MqoOlY9BmbPCFTqVdg.InA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MA--/https://media.zenfs.com/en/globenewswire.com/3e2f430d18dcba99f4639e0554ffa243","width":300,"height":107},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/MqoOlY9BmbPCFTqVdg.InA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MA--/https://media.zenfs.com/en/globenewswire.com/3e2f430d18dcba99f4639e0554ffa243","width":300,"height":107}},"lazy":false},{"type":"text","content":"REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended March 31, 2026 and provided a corporate update.","length":462,"tagName":"p"},{"type":"text","content":""In recent months, we have continued to advance the briquilimab development program in CSU," said Jeet Mahal, President and Chief Executive Officer of Jasper. “Following our positive clinical data update in January, we have conducted an analysis of the full data package from BEACON, SPOTLIGHT and the open-label extension study to drive the selection of two active dosing regimens to evaluate in our Phase 2b study. In parallel we have also updated and refiled the Phase 2b protocol with the FDA as we work to secure additional funding to enable commencement of the study in the second half of this year as planned.”","length":627,"tagName":"p"},{"type":"text","content":"Highlights for First Quarter 2025 and Recent Weeks","length":50,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Refiled an updated Phase 2b protocol with the FDA for the planned Phase 2b study of briquilimab in CSU.","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Jeet Mahal appointed as Chief Executive Officer to lead next phase of clinical growth.","length":86,"tag...